Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010, Article ID 517493, 8 pages
Review Article

Dendritic Cell-Based Immunotherapy for Prostate Cancer

1Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstr. 74, 01307 Dresden, Germany
2Department of Urology, Medical Faculty, Technical University of Dresden, 01307 Dresden, Germany
3Translational Sciences and Safety, Novartis Biologic, 4002 Basel, Switzerland
4Center for Regenerative Therapies Dresden, 01307 Dresden, Germany

Received 30 June 2010; Accepted 7 October 2010

Academic Editor: Yang Liu

Copyright © 2010 Hanka Jähnisch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.